5 recruiting. 5 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Recruiting 5 |
| Phase 2 | 1 | Recruiting 1 |
Follow Uremia: new trials by email Literature Review of Uremia trials Research Report on Uremia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Self-Controlled Study on the Treatment of Restless Legs Syndrome in Uremia With Dipyridamole Dipyridamole 50mg tid - Restless Leg Syndrome Due to Uraemia | Phase 2 / Phase 3 | Recruiting | Yunfeng Xia | 80 | 2025-09-20 | 2026-04-22 |
| Efficacy of INM004 in Children With STEC-HUS INM004, Placebo - Hemolytic-Uremic Syndrome | Phase 3 | Recruiting | Inmunova S.A. | 220 | 2024-10-05 | 2026-01-15 |
| Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS Iptcaopan 200 mg - Atypical Hemolytic Uremic Syndrome | Phase 3 | Recruiting | Novartis Pharmaceuticals | 65 | 2024-05-08 | 2026-06-04 |
| Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Iptacopan - Atypical Hemolytic Uremic Syndrome | Phase 3 | Recruiting | Novartis Pharmaceuticals | 50 | 2024-02-28 | 2026-04-29 |
| Eculizumab in Hypertensive Emergency-associated Hemolytic Uremic Syndrome Soliris®, Renin angiotensin system blockers - Hypertensive Emergency-associated Hemolytic Uremic Syndrome | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 66 | 2023-11-09 | 2024-01-05 |
Atypical Hemolytic Uremic Syndrome (3) · Thrombotic Microangiopathies (2) · Acute Kidney Injury (1) · Glomerulonephritis, Membranoproliferative (1) · Hemolytic-Uremic Syndrome (1) · Hypertensive Crisis (1) · Kidney Failure, Chronic (1) · Restless Legs Syndrome (1)
Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Kidney Diseases (5) · Male Urogenital Diseases (5) · Urogenital Diseases (5) · Urologic Diseases (5) · Anemia (4) · Anemia, Hemolytic (4) · Blood Platelet Disorders (4) · Cytopenia (4) · Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Thrombocytopenia (4) · Hemolytic-Uremic Syndrome (3)
Dipyridamole (1) · Exercise (1) · eculizumab (1) · iptacopan (1)
Novartis Pharmaceuticals (2) · Assistance Publique - Hôpitaux de Paris (1) · Inmunova S.A. (1) · Yunfeng Xia (1)
China (3) · France (3) · Germany (2) · Italy (2) · Japan (2) · Spain (2) · Turkey (Türkiye) (2) · United Kingdom (2) · Argentina (1) · Belgium (1) · Brazil (1) · Czechia (1) · India (1) · Ireland (1) · Romania (1)